VANCOUVER — October 27, 2025 Leads & Copy — Xenon Pharmaceuticals Inc. (TSX:XENE, Nasdaq:XENE) reported positive Phase 3 results for its lead epilepsy drug, XEN1101, clearing the path for a U.S. regulatory filing in early 2026 and lifting shares 9.4 percent this week.
The Vancouver-based company said the treatment showed statistically significant seizure reduction in adults with focal epilepsy, outperforming placebo across key endpoints. The data positions Xenon for milestone payments from licensing partners and a potential commercial launch by late next year.
CEO Ian Mortimer said the company is scaling manufacturing and preparing payer engagement strategies, with plans to expand its neurology pipeline through 2027.
Xenon shares are up 42 percent year-to-date, leading Canadian biotech performance.
